| scholarly article | Q13442814 |
| P50 | author | Christopher W Schultz | Q91061471 |
| P2093 | author name string | Wei Jiang | |
| Charles J Yeo | |||
| Liang Xu | |||
| Gloria H Su | |||
| Talia Golan | |||
| Michael J Pishvaian | |||
| Jonathan R Brody | |||
| Alex Haber | |||
| Aditi Jain | |||
| Teena Dhir | |||
| James Posey | |||
| Samantha Z Brown | |||
| Austin Goetz | |||
| Chunhua Xi | |||
| P2860 | cites work | Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer | Q26785691 |
| Selection criteria in resectable pancreatic cancer: a biological and morphological approach | Q26859742 | ||
| The retinoblastoma protein and cell cycle control | Q27860722 | ||
| CDK inhibitors: positive and negative regulators of G1-phase progression | Q27860983 | ||
| Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells | Q33692902 | ||
| Phenotype and genotype of pancreatic cancer cell lines | Q33814471 | ||
| Cyclin D activates the Rb tumor suppressor by mono-phosphorylation | Q33827900 | ||
| CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers | Q34004428 | ||
| Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine | Q34217662 | ||
| CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer | Q34227791 | ||
| Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils | Q34956634 | ||
| Identification and validation of novel small molecule disruptors of HuR-mRNA interaction | Q35573530 | ||
| A systems biology dynamical model of mammalian G1 cell cycle progression | Q35689859 | ||
| Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs | Q36005156 | ||
| The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway | Q36010739 | ||
| CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis | Q36084097 | ||
| HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. | Q36149317 | ||
| Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. | Q37564392 | ||
| Impact of cellular senescence in aging and cancer | Q38051711 | ||
| Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. | Q38786230 | ||
| Treating cancer with selective CDK4/6 inhibitors | Q38794109 | ||
| CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1. | Q38839758 | ||
| Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. | Q38922461 | ||
| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial | Q38994795 | ||
| The role and clinical significance of YES-associated protein 1 in human osteosarcoma | Q39175967 | ||
| The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies | Q39183079 | ||
| Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo | Q39437873 | ||
| Combenefit: an interactive platform for the analysis and visualization of drug combinations. | Q39788218 | ||
| Pro-senescent effect of hydrogen peroxide on cancer cells and its possible application to tumor suppression | Q39885940 | ||
| Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. | Q40176991 | ||
| Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis | Q40505799 | ||
| Loss of proliferative capacity and induction of senescence in oxidatively stressed human fibroblasts | Q40514053 | ||
| The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity | Q40525768 | ||
| Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease | Q41093656 | ||
| nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Q41501622 | ||
| Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells | Q42368968 | ||
| Preclinical characterization of abemaciclib in hormone receptor positive breast cancer | Q42378353 | ||
| Knockdown of Yes-Associated Protein Induces the Apoptosis While Inhibits the Proliferation of Human Periodontal Ligament Stem Cells through Crosstalk between Erk and Bcl-2 Signaling Pathways | Q43240295 | ||
| Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors | Q46137197 | ||
| Gemcitabine induces cell senescence in human pancreatic cancer cell lines | Q46531531 | ||
| CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease | Q47142001 | ||
| Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer | Q47590783 | ||
| 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. | Q48305554 | ||
| CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype | Q48820342 | ||
| A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. | Q53607571 | ||
| Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. | Q55380602 | ||
| Pancreatic cancer survival analysis defines a signature that predicts outcome | Q57136038 | ||
| CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought | Q57176702 | ||
| Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance | Q61805753 | ||
| Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas | Q71102397 | ||
| Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival | Q88435826 | ||
| YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer | Q90622509 | ||
| Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling | Q91068420 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 2029-2041 | |
| P577 | publication date | 2019-08-05 | |
| P1433 | published in | Molecular Cancer Research | Q2751014 |
| P1476 | title | Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition | |
| P478 | volume | 17 |
Search more.